Aerie has all the hallmarks of a promising early stage...

Aerie has all the hallmarks of a promising early stage biotechnology company. Initial animal testing has been very encouraging. Our products target a rapidly growing $3 billion dollar global market that has seen little innovation and is ripe for improvement. We have a seasoned team of senior executives who will successfully shepherd AR-101 into the clinic, and we have provided the necessary capital to get them there.